Transplanted neural stem cells: Playing a neuroprotective role by ceruloplasmin in the substantia nigra of PD model rats?

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Xiao, Jia Jia ^a   Yin, Ming ^a   Wang, Ze Jian ^a   Wang, Xiao Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DEPOSITION; GRAFTING (CHEMICAL); IRON; NEURODEGENERATIVE DISEASES; STEM CELLS;

DOPAMINERGIC NEURONS; IRON DEPOSITION; MICROENVIRONMENTS; NEURAL STEM CELL; PARKINSON'S DISEASE; SUBSTANTIA NIGRA; TYROSINE HYDROXYLASE; WILSON'S DISEASE;

NEURONS;

CERULOPLASMIN; IRON; TYROSINE 3 MONOOXYGENASE; ADRENERGIC RECEPTOR STIMULATING AGENT; MESSENGER RNA; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; STEREOTACTIC PROCEDURE; SUBSTANTIA NIGRA; ALLOTRANSPLANTATION; ANIMAL; BRAIN; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NEURAL STEM CELL; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TRANSPLANTATION;

RATTUS;

ADRENERGIC AGENTS; ANIMALS; BRAIN; CERULOPLASMIN; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; IRON; NEURAL STEM CELLS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTANTIA NIGRA; TRANSPLANTATION, HOMOLOGOUS; TYROSINE 3-MONOOXYGENASE;

EID: 84935017622     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/618631     Document Type: Article

References (46)

1. X. Tan, L. Zhang, H. Zhu et al., "Brn4 and TH synergistically promote the diferentiation of neural stem cells into dopamin-ergic neurons," Neuroscience Letters, vol. 571, pp. 23-28, 2014.
2. R. Pardal and J. López-Barneo, "Neural stem cells and transplantation studies in Parkinson's disease," Advances in Experimental Medicine and Biology, vol. 741, pp. 206-216, 2012.
3. T. Yasuhara, N. Matsukawa, K. Hara et al., "Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease," The Journal of Neuroscience, vol. 26, no. 48, pp. 12497-12511, 2006.
4. K. B. Bjugstad, Y. D. Teng, D. E. Redmond Jr. et al., "Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease," Experimental Neurology, vol. 211, no. 2, pp. 362-369, 2008.
5. K. K. Meissner, D. L. Kirkham, and L. C. Doering, "Transplants of neurosphere cell suspensions from aged mice are functional in the mouse model of Parkinson's," Brain Research, vol. 1057, no. 1-2, pp. 105-112, 2005.
6. Q. F. Zhu, J. Ma, L. L. Yu, and C. G. Yuan, "Grafed neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats," Neuroscience Letters, vol. 462, no. 3, pp. 213-218, 2009.
7. K. B. Bjugstad, D. E. Redmond Jr., Y. D. Teng et al., "Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: a return to control measures," Cell Transplantation, vol. 14, no. 4, pp. 183-192, 2005.
8. D. M. Hermann, L. Peruzzotti-Jametti, J. Schlechter, J. D. Bernstock, T. R. Doeppner, and S. Pluchino, "Neural precursor cells in the ischemic brain-integration, cellular crosstalk, and consequences for stroke recovery," Frontiers in Cellular Neuroscience, vol. 8, article 291, 2014.
9. C. Sun, H. Zhang, J. Li et al., "Modulation of the major histo-compatibility complex by neural stem cell-derived neurotrophic factors used for regenerative therapy in a rat model of stroke," Journal of Translational Medicine, vol. 8, article 77, 2010.
10. K. J. Doorn, B. Drukarch, A. van Dam, and P. J. Lucassen, "Hippocampal proliferation is increased in presymptomatic Parkinson's disease and due to microglia," Neural Plasticity, vol. 2014, Article ID 959154, 13 pages, 2014.
11. Z. H. Sun, Y. L. Lai, W. W. Zeng, D. Zhao, H. C. Zuo, and Z. P. Xie, "Neural stem/progenitor cells survive and diferentiate better in PD rats than in normal rats," Acta Neurochirurgica Supplement, vol. 87, pp. 169-174, 2003.
12. V. Vassiliev, Z. L. Harris, and P. Zatta, "Ceruloplasmin in neurodegenerative diseases," Brain Research Reviews, vol. 49, no. 3, pp. 633-640, 2005.
13. S. Olivieri, A. Conti, S. Iannaccone et al., "Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferrox-idase activity and promotes cellular iron retention," Journal of Neuroscience, vol. 31, no. 50, pp. 18568-18577, 2011.
14. +-evoked neurotoxicity in rats," Neuroscience Research, vol. 75, no. 3, pp. 250-255, 2013.
15. S. Ayton, P. Lei, P. A. Adlard et al., "Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease," Molecular Neurodegener-ation, vol. 9, no. 1, article 27, 2014.
16. A. McNeill, M. Pandolfo, J. Kuhn, H. Shang, and H. Miyajima, "The neurological presentation of ceruloplasmin gene mutations," European Neurology, vol. 60, no. 4, pp. 200-205, 2008.
17. W.-J. Li, J.-F. Wang, and X.-P. Wang, "Wilson's disease: update on integrated Chinese and western medicine," Chinese Journal of Integrative Medicine, vol. 19, no. 3, pp. 233-240, 2013.
18. S. Ayton, P. Lei, J. A. Duce et al., "Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease," Annals of Neurology, vol. 73, no. 4, pp. 554-559, 2013.
19. Y. Yu and T. Wen, "Generation of dopaminergic neurons by fusion of neural stem cells and midbrain neurons," Cellular and Molecular Biology, vol. 57, supplement, pp. OL1528-OL1533, 2011.
20. X. Deng, Y. Liang, H. Lu et al., "Co-transplantation of GDNF-overexpressing neural stem cells and fetal dopaminergic neurons mitigates motor symptoms in a rat model of parkinson's disease," PLoS ONE, vol. 8, no. 12, Article ID e80880, 2013.
21. G. Paxinos and C. Watson, The Rat Brain Stereotaxic Coordinates, Academic Press, Sydney, Australia, 2006.
22. L. Frau, M. Morelli, and N. Simola, "Performance of movement in hemiparkinsonian rats infuences the modifcations induced by dopamine agonists in striatal eferent dynorphinergic neurons," Experimental Neurology, vol. 247, pp. 663-672, 2013.
23. X.-X. Du, H.-M. Xu, H. Jiang, N. Song, J. Wang, and J.-X. Xie, "Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease," Neuroscience Bulletin, vol. 28, no. 3, pp. 253-258, 2012.
24. J. Wang, H. Xu, H. Jiang, X. Du, P. Sun, and J. Xie, "Neurores-cue efect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson's disease," Journal of Molecular Neuroscience, vol. 47, no. 1, pp. 113-119, 2012.
25. L. Li, C. Holscher, B.-B. Chen, Z.-F. Zhang, and Y.-Z. Liu, "Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus," Biological Trace Element Research, vol. 143, no. 3, pp. 1581-1593, 2011.
26. Y. Li, Y. Sun, J. Yang, Y. Wu, J. Yu, and B. Li, "Age-dependent dopaminergic dysfunction following fetal exposure to atrazine in SD rats," Environmental Toxicology and Pharmacology, vol. 37, no. 3, pp. 1275-1282, 2014.
27. J. Y. Lee, S. H. Kim, A.-R. Ko et al., "Terapeutic efects of repetitive transcranial magnetic stimulation in an animal model of Parkinson's disease," Brain Research, vol. 1537, pp. 290-302, 2013.
28. R. K. Leak, K. A. Garbett, A. M. Dettmer, Z. Zhang, K. Mirnics, and J. L. Cameron, "Physical activity is linked to ceruloplasmin in the striatum of intact but not MPTP-treated primates," Cell and Tissue Research, vol. 350, no. 3, pp. 401-407, 2012.
29. M. Biebl, B. Winner, and J. Winkler, "Caspase inhibition decreases cell death in regions of adult neurogenesis," NeuroReport, vol. 16, no. 11, pp. 1147-1150, 2005.
30. J. Ourednik, V. Ourednik, W. P. Lynch, M. Schachner, and E. Y. Snyder, "Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons," Nature Biotechnology, vol. 20, no. 11, pp. 1103-1110, 2002.
31. X. Zhang, J. Xiong, S. Liu et al., "Puerarin protects dopamin-ergic neurons in Parkinson's disease models," Neuroscience, vol. 280, pp. 88-98, 2014.
32. C. Krabbe, S. T. Bak, P. Jensen et al., "Infuence of oxygen tension on dopaminergic diferentiation of human fetal stem cells of midbrain and forebrain origin," PLoS ONE, vol. 9, no. 5, Article ID e96465, 2014.
33. X.-L. Gu, C.-X. Long, L. Sun, C. Xie, X. Lin, and H. Cai, "Astro-cytic expression of Parkinson's disease-related A53T-synuclein causes neurodegeneration in mice," Molecular Brain, vol. 3, no. 1, article 12, 2010.
34. D. Ziavra, G. Makri, P. Giompres et al., "Neural stem cells transplanted in a mouse model of Parkinson's disease diferentiate to neuronal phenotypes and reduce rotational defcit," CNS and Neurological Disorders-Drug Targets, vol. 11, no. 7, pp. 829-835, 2012.
35. A. Wypijewska, J. Galazka-Friedman, E. R. Bauminger et al., "Iron and reactive oxygen species activity in parkinsonian substantia nigra," Parkinsonism and Related Disorders, vol. 16, no. 5, pp. 329-333, 2010.
36. R. L. Schroeder and J. P. Gerber, "A reappraisal of Fe(III) adsorption by melanin," Journal of Neural Transmission, vol. 121, no. 12, pp. 1483-1491, 2014.
37. G. Bartzokis, P. H. Lu, K. Tingus et al., "Gender and iron genes may modify associations between brain iron and memory in healthy aging," Neuropsychopharmacology, vol. 36, no. 7, pp. 1375-1384, 2011.
38. D. Kaur and J. Andersen, "Does cellular iron dysregulation play a causative role in Parkinson's disease?" Ageing Research Reviews, vol. 3, no. 3, pp. 327-343, 2004.
39. M. R. Hennis, K. W. Seamans, M. A. Marvin, B. H. Casey, and M. S. Goldberg, "Behavioral and neurotransmitter abnormalities in mice defcient for Parkin, DJ-1 and superoxide dismutase," PLoS ONE, vol. 8, no. 12, Article ID e84894, 2013.
40. J. Kristinsson, J. Snaedal, G. Tórsdóttir, and T. Jóhannesson, "Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies," Neuropsychiatric Disease and Treatment, vol. 8, pp. 515-521, 2012.
41. S. A. Schneider, P. Dusek, J. Hardy, A. Westenberger, J. Jankovic, and K. P. Bhatia, "Genetics and pathophysiology of neurode-generation with brain iron accumulation (NBIA)," Current Neuropharmacology, vol. 11, no. 1, pp. 59-79, 2013.
42. T. Litwin, G. Gromadzka, G. M. Szpak, K. Jabłonka-Salach, E. Bulska, and A. Członkowska, "Brain metal accumulation in Wilson's disease," Journal of the Neurological Sciences, vol. 329, no. 1-2, pp. 55-58, 2013.
43. L. Batista-Nascimento, C. Pimentel, R. A. Menezes, and C. Rodrigues-Pousada, "Iron and neurodegeneration: from cellular homeostasis to disease," Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 128647, 8 pages, 2012.
44. I. de Domenico, D. M. Ward, M. C. B. di Patti et al., "Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin," The EMBO Journal, vol. 26, no. 12, pp. 2823-2831, 2007.
45. K. Kaneko, A. Hineno, K. Yoshida, and S.-I. Ikeda, "Increased vulnerability to rotenone-induced neurotoxicity in ceruloplas-min-defcient mice," Neuroscience Letters, vol. 446, no. 1, pp. 56-58, 2008.
46. S. J. Texel, X. Xu, and Z. L. Harris, "Ceruloplasmin in neurode-generative diseases," Biochemical Society Transactions, vol. 36, no. 6, pp. 1277-1281, 2008.